Viriom presented the results of an international double-blind, randomized, placebo-controlled Phase Ib/IIa clinical trial of a new antiviral drug VM-1500 in HIV patients at the Conference on Retroviruses And Opportunistic Infections (CROI 2014) held in Boston, MA. Advantages of VM-1500 over known HIV therapies using nucleoside reverse transcriptase inhibitors were demonstrated.
The study was performed at Siriraj Hospital, Mahidol University, Thailand on cohort of 16 treatment-naïve patients. The goals of the trial were to determine antiviral efficacy, safety and human PK profile of the drug.
Poster presentation was done by Dr.Winai Ratanasuwan, Principal Investigator, Siriraj Hospital, Mahidol University, Dr. Robert Murphy, Scientific Advisor, Viriom Ltd. and Dr. Vadim Bichko, CSO, Viriom Ltd.
The presented results of the study suggested that VM-1500 has high antiviral efficacy (the viral titers in plasma decreased on 1.73 log10 after 7 days treatment even at lower doses of 20 mg), good safety and excellent PK profile in humans.